Ishita Drugs & Industries Ltd Fair Value
ISHITADRUGSINDUSLTD · Healthcare · Current price
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹37 | 8% ROE fading to 12% over ~3 yrs, on ₹39 book |
| Relative P/E | ₹96 | EPS × 38.2 peer-median P/E |
| Graham floor | ₹47 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | — | No analyst coverage |
Is Ishita Drugs & Industries Ltd undervalued?
We couldn't compute a reliable fair value for Ishita Drugs & Industries Ltd from the available data. This usually means key inputs (earnings, book value, or cash flow) are missing or inconsistent.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹37), Relative P/E (₹96), Graham floor (₹47). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹37 (bear) to ₹55 (base) to ₹96 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on Ishita Drugs & Industries Ltd
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.